Trialwise, Inc. is proud to be a CRO partner of SRI International in developing an oral treatment for radioactive poisoning. SRI International has engaged Trialwise to provide clinical operations, data management...
Results from an early phase study supported by Trialwise indicate that an ophthalmic emulsion developed by Skye Bioscience as a potential treatment for glaucoma has been well-tolerated in healthy volunteers.
A multi-site Phase 1 clinical trial of up to three dozen participants living with HIV is receiving the benefits of the rollout of Trialwise’s proprietary framework to enable risk-based monitoring in early phase clinical trials....
